Filing Details
- Accession Number:
- 0001209191-17-028039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-04-24 20:58:12
- Reporting Period:
- 2017-04-24
- Filing Date:
- 2017-04-24
- Accepted Time:
- 2017-04-24 20:58:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 818033 | Heron Therapeutics Inc. | HRTX | Pharmaceutical Preparations (2834) | 942875566 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1202094 | Kimberly Manhard | 4242 Campus Point Court Suite 200 San Diego CA 92121 | Executive Vp, Drug Development | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-04-24 | 5,250 | $8.80 | 5,250 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2017-04-24 | 16,292 | $9.05 | 21,542 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-04-24 | 21,542 | $15.33 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-04-24 | 5,250 | $0.00 | 5,250 | $8.80 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-04-24 | 16,292 | $0.00 | 16,292 | $9.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-01-10 | No | 4 | M | Direct | |
| 0 | 2024-12-12 | No | 4 | M | Direct |
Footnotes
- The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in March 2017.
- The range of sales prices received was $15.125 to $15.60. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (01/10/2014).
- The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the date of grant (12/12/2014).
Billionaire Hedge Funds
